AzTrials
AzTrials

Neonatal Respiratory DistressPhase 4NCT02978976

Effect of Antenatal Steroid on Pulmonary Artery Blood Flow

A Phase 4 study testing Betamethasone and saline in people with Neonatal Respiratory Distress, run by Kasr El Aini Hospital at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The aim of this study is to determine the effect of administering antenatal steroids in term fetuses on the blood flow in the fetal pulmonary artery, and to correlate these findings with clinical data obtained after birth documenting respiratory disorders. Read more about this study

Who is it for?
Ages 28 to 38 years, women onlyHealthy volunteers can take part
Conditions the study is for
Neonatal Respiratory Distress
What is being tested?
Betamethasone and saline
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
126 participants
Where
1 siteEgypt
Study dates
Jan 2017to May 2018
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 28 to 38 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • indication for elective caesarean section.
  • 37weeks +6days

Who cannot join

  • hypertensive
  • diabetic
  • any disorder that may be aggravated by administration of steroids
  • women with systemic infection including tuberculosis or sepsis
  • any fetal congenital anomalies (affecting the fetal heart, lungs, and circulation)
  • history of rupture membranes, or suspected chorioamnionitis
  • intrauterine growth retardation (IUGR)
  • intrauterine fetal demise (IUFD).

Trial locations and contacts

1 site in 1 country.

Ahmed M Kamel, M.D. contact

00201120022332

dr.ahmed.m.kamel@gmail.com

Emad Salah, M.D. contact

emadsalah148@gmail.com

Egypt1 site, 1 recruiting
  • 11562

    Cairo, 11562

    Ahmed M KameL, M.D, 01120022332, dr.ahmed.m.kamel@gmail.com

    Recruiting

Other trials in Egypt

About this study

Official title: The Effect of Maternal Antenatal Steroid Administration on the Blood Flow Through the Pulmonary Artery in the Term Fetus; a Randomized Control Double Blinded Study

The aim of this study is to determine the effect of administering antenatal steroids in term fetuses on the blood flow in the fetal pulmonary artery, and to correlate these findings with clinical data obtained after birth documenting respiratory disorders.

Read the detailed description

After internal review board approval, 126 consecutive patients attending the antenatal care clinic of Kasr Alainy Hospital, part of Cairo university hospitals will be recruited in this study. All patients will sign informed consent.

Patients included in the study will be 20-38 years of age, have an indication for elective caesarean section. Patients will be excluded if they are hypertensive, diabetic or have any disorder that may be aggravated by administration of steroids, women with systemic infection including tuberculosis or sepsis, any fetal congenital anomalies (affecting the fetal heart, lungs, and circulation), history of rupture membranes, or suspected chorioamnionitis, intrauterine growth retardation (IUGR), and intrauterine fetal demise (IUFD).

Patients will be randomized on 37 weeks and 6 days gestation by the nurse attending the clinic using a computer generated randomization table, and a closed envelope system will be used. Patients will be equally divided into two groups. Patients in group (A) will receive two doses of 12mg betamethasone ( Dipropfos ® SCHERING-PLOUGH; Kenilworth, New Jersey, USA) intramuscularly (IM) 24 hours apart, while group (B) patients will receive a saline placebo injection in the same regimen.

Ultrasound examination will be done where all patients will lie down in a semi-recumbent position, and the ultrasound will be performed by an expert ultrasonographer, with expert training in fetal echocardiography. The ultrasound specialist will be blinded to which study arm the patients belongs. The abdominal probe of the ultrasound machine (voluson730; kretz,Zipf,Austria) will be placed so that the fetal chest will be in a transverse section, giving us the four chamber view of the fetal heart. The color Doppler will then be switched on, and the fetal pulmonary artery will be identified. The measurements will be taken from the middle segment of the pulmonary artery just after the first bifurcation of the pulmonary branch (just after crossing the aortic arch). We will obtain our measurements from either the right or left pulmonary arteries, whichever is easier according to fetal position, as there is no difference between the values obtained from either according to the work done by Rasanen et al.

The pulsatility index (PI), resistance index (RI), systolic/diastolic ratio (SD), and the acceleration-time/ejection-time ratio (At/Et) will be determined in all cases after recruitment, just before the administration of the drug (betamethasone / placebo), 24 hours after the last dose, and on the day of elective Cs. Caesarean section will be performed 7 days after the last dose of betamethasone, and a senior neonatologist will attend the birth, document Apgar score, and any neonatal respiratory distress.

A sample size was calculated where the difference in the mean pulsatility index (PI) before and after administration of antenatal steroids for the middle segment of the fetal pulmonary artery was 0.42 in a previous study by Bartha et al, and the standard deviation was set as 0.79. The Type I error probability was set at 0.05, and the power at 80%. This gave us 57 patients in each arm, and allowing for dropout rate of 10%, 63 patients will be recruited in each arm of the study, as the ratio between both study and control was 1:1. PS Power and Sample size Calculations software, Versionv2.1.30 for MS Windows, was used to calculate sample size Dupont and Vanderbilt, USA).

Being tested
Betamethasone, saline
Keywords
RDS, Doppler on fetal pulmonary artery
Medical subject headings
Pulmonary Atelectasis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BetamethasoneDrug

    Also called Dipropfos

    will receive two doses of 12mg betamethasone ( Dipropfos ® SCHERING-PLOUGH; Kenilworth, New Jersey, USA) intramuscularly (IM) 24 hours apart.

  • salineDrug

    Also called NaCl 0.9

    saline placebo injection in the same regimen.

Study groups in NCT02978976
Study groupRoleWhat they receive
betamethasoneExperimentalwill receive two doses of 12mg betamethasone, then the pulsatility index (PI), resistance index (RI), systolic/diastolic ratio (SD), and the acceleration-time/ejection-time ratio (At/Et) will be determined in all cases after recruitment, just before the administration of the drug (betamethasone), 24 hours after the last dose, and on the day of elective Cs.
Receives: Drug: Betamethasone
SalinePlacebo comparatorwill receive saline injection placebo, then the pulsatility index (PI), resistance index (RI), systolic/diastolic ratio (SD), and the acceleration-time/ejection-time ratio (At/Et) will be determined in all cases after recruitment, just before the administration of the drug ( placebo), 24 hours after the last dose, and on the day of elective Cs.
Receives: Drug: saline

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. changes in the mean doppler parameters between the study groups before and after the drug administration ( compare means of doppler reading between both groups using t-test)

    Measured: 1 week

Secondary outcomes (1)
  1. Presense of respiratory disorders in neonate (yes/no)

    Measured: 8 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Dec 2016 (estimated)
  2. Study startJan 2017
  3. Primary completionApr 2018 (estimated)
  4. Study completionMay 2018 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
126 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02978976
Sponsor's protocol ID
A22102016
Status last verified
Nov 2017
First submitted
22 Oct 2016
Last updated
17 Nov 2017
Results posted
No
Data monitoring committee
No
Individual data sharing
Yes: yes

Publications

  • Bartha JL, Largo-Heinrich M, Machado MJ, Gonzalez-Bugatto F, Hervias-Vivancos B. Effects of antenatal betamethasone on human fetal branch pulmonary artery flow velocity waveforms. Fetal Diagn Ther. 2008;23(1):46-53. doi: 10.1159/000109226. Epub 2007 Oct 9.

    PubMed 17934298

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Betamethasone and saline in people with Neonatal Respiratory Distress, run by Kasr El Aini Hospital at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 17 Nov 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Ahmed M Kamel, M.D. (00201120022332, dr.ahmed.m.kamel@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

changes in the mean doppler parameters between the study groups before and after the drug administration ( compare means of doppler reading between both groups using t-test) (time frame: 1 week). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02978976, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Nov 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in